Ligand Announces Clinical and Regulatory Progress by Multiple Partners with OmniAb® AntibodiesBusiness Wire • 11/23/20
Ligand's Partner Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ for the Treatment of Status Epilepticus in Adult and Pediatric PatientsBusiness Wire • 11/06/20
Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 10/30/20
Ligand Pharmaceuticals (LGND) Q3 Earnings and Revenues Miss EstimatesZacks Investment Research • 10/30/20
4 Health Stocks Stonepine Capital Loves (1 Has Gained 233% Since September 29)Insider Monkey • 10/26/20
Ligand's Captisol Technology Plays Key Role in the Manufacture of Gilead's Veklury, the First FDA-Approved COVID-19 TreatmentBusiness Wire • 10/23/20
Need to Know: Why the time is right for a bet on Caesars and 2 other unloved stocks, says this fourth-generation money managerMarket Watch • 10/22/20
Week In Review: Curon Bio Acquires Rights To Lymphoma Drug In $150 Million DealSeeking Alpha • 10/18/20
Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 MillionBusiness Wire • 09/23/20